Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370109 · ClinicalTrials.gov registry record
Cardiovascular Effects of Sunitinib Therapy (CREST)
A clinical trial of Renal Cell Carcinoma 4, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 98
- Enrollment target
- 1
- Study location
NCT01370109: Completed study of Renal Cell Carcinoma 4, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01370109 is a study of Renal Cell Carcinoma 4 that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 98 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01370109, a study of Renal Cell Carcinoma 4, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
Tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern. However, the mechanisms of these effects in humans remains poorly defined, as are the clinical methods to risk stratify and identify patients who will ultimately suffer from cardiac dysfunction. The goal of this multi-center study is to characterize the cardiovascular measures of cardiac function; 2) comprehensive measures of arterial function and left ventricular afterload; 3) biomarkers reflective of the pathophysiologic alterations. Through this work, the investigators will translate our basic understanding of sunitinib cardiotoxicity to humans and identify early predictors of sunitinib cardiotoxicity.
Conditions Studied
Study Locations (1)
Pennsylvania
- Abramson Cancer Center, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2011-04 |
| Est. Completion | 2017-12-31 |
What the finished NCT01370109 record still lists
NCT01370109 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 1 condition, with Renal Cell Carcinoma 4 appearing as the primary indexed condition, and to 0 interventions.
NCT01370109 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01370109 about?
NCT01370109 is a clinical study titled "Cardiovascular Effects of Sunitinib Therapy (CREST)". Tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern. However, the mechanisms of these effects in humans remains poorly defined,...
What is the current status of trial NCT01370109?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2011-04. Estimated completion is 2017-12-31.
What conditions does trial NCT01370109 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma 4.
Who is sponsoring clinical trial NCT01370109?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01370109 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia